PRESS RELEASE WOONSOCKET.

The Pharmacy Services and Retail Pharmacy segments both benefited from the effect of increased generic medicines dispensed. The Pharmacy Solutions Segment was positively impacted by development in specialty pharmacy along with favorable purchasing and rebate economics, partially offset by price compression. The Retail Pharmacy Segment was positively influenced by increased sales, a better front store margin rate largely driven by the removal of tobacco items and favorable purchasing economics, offset simply by reimbursement pressure partially. Adjusted earnings per talk about for the 90 days ended March31, 2015 and 2014, was$1.14and$1.02, respectively, a rise of 12.2 percent. Adjusted EPS in the 90 days endedMarch 31, excludes$129 millionand$131 millionin 2015 and 2014, respectively, of intangible asset amortization related to acquisition activity.We have a tradition of providing assistance around the world when disasters occur’ stated Mr. Jack Kay, President & COO of Apotex Inc.. BMS Licenses Peptidream Technology, Extends Collaboration PeptiDream said today it decided to permit nonexclusively its Peptide Discovery System Program technology to Bristol-Myers Squibb , aswell as to another expansion of a related collaboration-;a nearly three-year-aged macrocyclic peptide medication discovery alliance-;with the pharma giant. The PDPS technology permit was predicated on the successes accomplished during the first 3 years of our discovery collaboration with Bristol-Myers Squibb, PeptiDream CEO Kiichi Kubota stated in a declaration.